AhR and Pulmonary Hypertension: A Potential Therapeutic Target

The AhR (aryl hydrocarbon receptor) is a transcription factor that plays a crucial role in various physiological and pathological processes, including inflammation and immune responses. Recent studies have suggested that AhR activation may also be involved in the pathogenesis of pulmonary hypertension (PH).

PH is a progressive and debilitating disease characterized by increased pulmonary vascular resistance and elevated pulmonary arterial pressure, leading to right ventricular dysfunction and heart failure. The exact mechanisms underlying PH are not fully understood, but oxidative stress, inflammation, and immune dysfunction are believed to play important roles.

Studies have shown that AhR activation can promote inflammation and oxidative stress in the lungs, which may contribute to the development of PH. In preclinical models of PH, AhR activation has been shown to increase pulmonary vascular resistance, pulmonary artery pressure, and right ventricular hypertrophy.

Furthermore, AhR expression is increased in the lungs of PH patients, and AhR-target genes are upregulated in PH animal models. These findings suggest that AhR may be a potential target for the treatment of PH.

In conclusion, AhR activation may contribute to the pathogenesis of PH by promoting inflammation and oxidative stress in the lungs. Further studies are needed to fully understand the role of AhR in PH and its potential as a therapeutic target.